comparemela.com
Home
Live Updates
Jaguar Health, Inc.: Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea : comparemela.com
Jaguar Health, Inc.: Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Primary endpoint based on patient reported outcomes from study expected in October 2023With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described
Related Keywords
Italy ,
United States ,
Milan ,
Lombardia ,
Italian ,
Lisa Conte ,
Pravin Chaturvedi ,
Pabloc Okhuysen ,
Darlene Horton ,
Eric Roeland ,
Company Current Report On Form ,
Jaguar Health Inc View ,
Napo Therapeutics Jaguar Animal Health ,
Jaguar Health ,
Jaguar Health Inc ,
Nasdaq ,
Napo Pharmaceuticals Inc ,
Exchange Commission On ,
Exchange Commission ,
Napo Pharmaceuticals ,
Jaguar Animal Health ,
Jaguar Common Stock ,
Securities Act ,
Current Report ,
Chief Medical ,
Scientific Advisory Board ,
Chief Scientific ,
Cancer Therapy Related Diarrhea ,
Napo Therapeutics ,
Jaguar Animal ,
Inc View ,
Gefallene Big Techs ,
Jaguar ,
Health ,
Ompletes ,
Enrollment ,
Pivotal ,
Hase ,
Intarget ,
Trial ,
Crofelemer ,
Prophylaxis ,
Dancer ,
Therapy ,
Elated ,
Diarrhea ,
comparemela.com © 2020. All Rights Reserved.